Welcome to DailyUpdates Oncology Channel - the R&D community's bulletin of breaking research, clinical trials and drug development news. This page will update each day. You have access for 1 more day(s). To receive DailyUpdates by e-mail register here


PubMed DailyUpdates: Breaking Scientific Publications for the Drug Discovery Community

DailyUpdates by e-mail - the publication tracker for the drug discovery community

Oncology Channel



If this icon appears after any of our listed articles, the author is able to provide reprints. Articles denoted by an Licensing Op. icon describe data relevant to licensing opportunities. The report icon, , links through to full analyses relating to pharmaceutical/market developments relating to this work

Facebook

Today's headline articles

Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts.

Today's journal articles

c-Met-mediated reactivation of PI3K/AKT signaling contributes to insensitivity of BRAF(V600E) mutant thyroid cancer to BRAF inhibition.

Do you need further information on any of the agents being evaluated in the trial(s) below?  Let us know...

New Clinical Trials

An Open Label, Non-randomized Phase II Trial Evaluating WNT974 in Patients With Metastatic Head and Neck Squamous Cell Carcinoma

LY2606368 in Combination With Cytarabine and Fludarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HRMDS)

Study of the Safety, Tolerability and Efficacy of KPT-8602 in Patients With Relapsed/Refractory Multiple Myeloma

Previous Journal Entries

Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD(®) immunomodulatory drug pomalidomide.

Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736.

Tyrosine Kinase Inhibitors as a First-Line Treatment in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: A Mixed-Treatment Comparison.

High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma.

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.

Antitumoral activity of the mithralog EC-8042 in triple negative breast cancer linked to cell cycle arrest in G2.

Mature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation.

A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer.

The vascular disrupting activity of OXi8006 in endothelial cells and its phosphate prodrug OXi8007 in breast tumor xenografts.

AMPK Protects Leukemia-Initiating Cells in Myeloid Leukemias from Metabolic Stress in the Bone Marrow.

PARP inhibitors sensitize Ewing sarcoma cells to Temozolomide-induced apoptosis via the mitochondrial pathway.

Interferon-β Modulates the Innate Immune Response against Glioblastoma Initiating Cells.

miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity.

PDK1 promotes tumor growth and metastasis in a spontaneous breast cancer model.

Celecoxib enhances [sorafenib + sildenafil] lethality in cancer cells and reverts platinum chemotherapy resistance.

TTK activates Akt and promotes proliferation and migration of hepatocellular carcinoma cells.

Heme oxygenase-1 in macrophages controls prostate cancer progression.

Visualizing the antivascular effect of bortezomib on the hypoxic tumor microenvironment.

Novel 3 - substituted 7 - Phenylpyrrolo[3,2 - f]quinolin - 9(6H) - ones as Single Entities with Multitarget Antiproliferative Activity.

Synthesis and anti-cancer activity of novel thiazolidinone analogs of 6-aminoflavone.

Today's News Items

Novartis CDK4/6 inhibitor LEE011 (ribociclib) receives FDA Breakthrough Therapy designation as first-line treatment for HR+/HER2- advanced breast cancer

PharmaMar initiates a pivotal Phase III ATLANTIS study with PM1183 in combination with doxorubicin in patients with small cell lung cancer

Training Courses & Meetings

No events listed

Previous News Items

Ipsen and its partner Exelixis receive positive CHMP opinion for Cabometyx™ (cabozantinib) for the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy

Puma Biotechnology Announces Interim 5-Year Disease Free Survival Data from Phase III Trial of PB272 (Neratinib) in Extended Adjuvant HER2-Positive Early Stage Breast Cancer (ExteNET Trial)

Puma Biotechnology Submits New Drug Application for PB272 (Neratinib) to U.S. FDA for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

OSI Pharmaceuticals Announces Launch of Tarceva

Merrimack Announces ONIVYDE® Regimen Receives Positive CHMP Opinion in European Union

Celgene and LYSARC Provide Update on the Phase III ‘REMARC' Study of REVLIMID® Maintenance Treatment in Patients with Diffuse Large B-Cell Lymphoma Responding to First-Line R-CHOP Therapy

Asuragen’s QuantideX® qPCR BCR-ABL IS Kit Receives FDA Premarket Clearance for Monitoring Minimal Residual Disease in Chronic Myeloid Leukemia

Celgene and LYSARC Provide Update on the Phase III ‘REMARC' Study of REVLIMID® Maintenance Treatment in Patients with Diffuse Large B-Cell Lymphoma Responding to First-Line R-CHOP Therapy

EISAI RECEIVES POSITIVE CHMP OPINION ON NEW INDICATION FOR ANTICANCER AGENT LENVATINIB IN COMBINATION WITH EVEROLIMUS FOR TREATMENT OF ADVANCED RENAL CELL CARCINOMA

Eisai And Halozyme Initiate Phase 1b/2 Clinical Trial With First Patient Dosing Of Eribulin In Combination With PEGPH20

Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Trial With KEYTRUDA